ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,341.41
-0.22%
Dow Jones
44,705.53
-0.17%
Gold vs US Dollar
2,638.27
-0.17%
Brent Oil
73.61
0.01%
Bitcoin
96,872.23
0.93%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) News

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALNY
DateTimeSourceHeadlineSymbolCompany
27/11/202422:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/11/202422:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/11/202422:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/11/202422:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/11/202422:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/11/202421:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/11/202412:00Business WireAlnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:ALNYAlnylam Pharmaceuticals Inc
25/11/202412:00Business WireAlnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/11/202414:30Business WireAlnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single DoseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/11/202413:00Business WireAlnylam to Webcast Presentations at Upcoming November Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
31/10/202412:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
31/10/202412:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
31/10/202412:00Business WireAlnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/10/202412:00Business WireAlnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024NASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/10/202412:15PR Newswire (Canada)Alnylam Canada signe une lettre d'intention de l'Alliance pharmaceutique pancanadienne (APP) pour le remboursement public d'AMVUTTRA pour le traitement de l'amylose héréditaire à transthyrétine (ATTRh) chez les adultesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/10/202413:12Business WireAlnylam dépose une demande d’autorisation de mise sur le marché auprès de l’Agence européenne des médicaments pour le vutrisiran dans le cadre du traitement de l’amylose ATTR avec cardiomyopathieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/10/202413:12Business WireAlnylam reicht bei der Europäischen Arzneimittelagentur einen Zulassungsantrag für Vutrisiran zur Behandlung von ATTR-Amyloidose mit Kardiomyopathie einNASDAQ:ALNYAlnylam Pharmaceuticals Inc
17/10/202412:00Business WireAlnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
16/10/202412:00Business WireAlnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyNASDAQ:ALNYAlnylam Pharmaceuticals Inc
10/10/202420:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/10/202411:00Business WireAlnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with CardiomyopathyNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/10/202420:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/10/202420:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/09/202413:00Business WireAlnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024NASDAQ:ALNYAlnylam Pharmaceuticals Inc
26/09/202412:00Business WireAlnylam to Webcast TTR Investor DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202420:03Business WireAlnylam présente les résultats détaillés de l'étude de phase 3 HELIOS-B positive de Vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie au congrès de la Société européenne de cardiologieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202417:10Business WireAlnylam präsentiert detaillierte Ergebnisse der positiven HELIOS-B-Phase-3-Studie mit Vutrisiran▼ bei Patienten mit ATTR-Amyloidose mit Kardiomyopathie auf dem Kongress der Europäischen Gesellschaft für KardiologieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202410:00Business WireAlnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology CongressNASDAQ:ALNYAlnylam Pharmaceuticals Inc
28/08/202420:00Business WireAlnylam to Webcast Presentations at Upcoming September Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
23/08/202400:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALNY

Your Recent History

LSE
SBTX
Skinbiotherapeutics
LSE
SCLP
Scancell
LSE
LGEN
Legal & General
LSE
POS
Plexus
LSE
GGP
Greatland Gold
LSE
THG
Thg
LSE
KEFI
Kefi Gold And Copper
LSE
ENET
Ethernity Networks
LSE
PANR
Pantheon Resources
LSE
BARC
Barclays
LSE
EME
Empyrean Energy
LSE
ORCP
Oracle Power
LSE
TERN
Tern
LSE
EZJ
Easyjet
LSE
NEXN
Nexxen
LSE
BOO
Boohoo
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved